Recursion Pharmaceuticals
AI-discovered treatments for unmet disease
Recursion Pharmaceuticals is a clinical-stage TechBio company expediting drug discovery using experimental biology, bioinformatics, and AI. Its proprietary Recursion OS integrates automation, data collection, and machine learning to industrialize drug discovery, aiming to reduce failure rates.
How We Help
Problem Statement
The high failure rate and slowness of traditional drug discovery.
Core Technology
experimental biology, bioinformatics, and artificial intelligence (AI)
Key Differentiators
testing up to 2.2 million samples per week; accelerating target identification to IND-enabling studies in less than 18 months (vs. 42 months); largest supercomputer in the pharmaceutical industry (BioHive-2)
Clinical Focus
aggressive cancers; rare diseases
Company Info
- Business Model
- B2B
- Total Funding
- 676,000,000
- Website
- recursion.com
Categories
Technologies
Clinical & IP
Clinical Validation
REC-4881 Phase 1b/2 positive results: 43% median polyp reduction, 75% of patients with improved polyp burden, 40% achieved clinically meaningful Spigelman stage improvement. FDA Fast Track and Orphan Drug designations. Sanofi achieved initial milestones on five programs (Q1 2025: $7M payment). Roche partnership generated $60M in milestones on neuroscience and oncology maps.
MedStartr Index Score
?What do you think of Recursion Pharmaceuticals?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.